Phase 1/2 Study of PARG Inhibitor ETX-19477 in Patients with Advanced Solid Malignancies

Brief description of study

This study is designed to test how the drug moves through the body (pharmacokinetics), how it works (pharmacodynamics), and how well it fights tumors. The drug being tested is ETX-19477, which targets a specific protein in cancer cells. The study has two parts: Phase 1 will test different doses of the drug to find the dose with the least amount of side effects that works, and Phase 2 will look at how well that dose works for treating cancer. In Phase 1, patients will be given different amounts of the drug to see which dose is best tolerated, starting with small doses and increasing them if it’s safe. Researchers will keep track of patients’ health and any side effects, and check how well the drug helps shrink the tumors. The goal is to find the best dose and learn how well ETX-19477 works against advanced cancers.


Clinical Study Identifier: s24-01637
ClinicalTrials.gov Identifier: NCT06395519
Principal Investigator: Nancy Chan.
Other Investigators: Elaine Shum, Kristen Spencer, Scot Niglio, Cindy Corbo, Christina Grace Wilson, Danielle Seidman, Eneil De La Pena, Maria Francis, Sarah Saerohm Lee, Fabia Brisard Pierrot, Mariam M Cheaib, Leslie R Boyd, Marina Stasenko, Jessica Wang, Olivia Richardson Khouri, Janice Mehnert, Joshua K Sabari, Keriann M Scavone, Kirby Rodriguez, Nina Beri, Rajwanth Veluswamy, Alexander A Hindenburg, David R. Wise, Douglas K Marks, Salman Rafi Punekar, Michelle Diane Swanson Lightfoot, Emeline Mariam Aviki, Paul E. Oberstein, Whitfield B. Growdon, Amanda Marie Buzolich, Anastasiya Apanasyuk, Zujun Li, Victoria Helen Dowd, Samantha VanMaanen, Kelly A Levine, Edward A Jimenez, Erin Annette Reese, Kathleen M Madden, Bhavana Pothuri, Ruth A White, Matthew A. Ingham, Kathleen M Lutz.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.